AI assistant
Inmune Bio, Inc. — Director's Dealing 2021
Jun 15, 2021
34518_dirs_2021-06-15_f88f345f-d005-4dbf-ad3e-aa7274b97276.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Inmune Bio, Inc. (INMB)
CIK: 0001711754
Period of Report: 2021-06-14
Reporting Person: Schroeder Timothy j (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-14 | Common Stock | S | 10000 | $19.0200 | Disposed | 136667 | Indirect |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $19.00 to $19.01, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.
F3: These shares of Common Stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares.